cardiometabolic disease
- Business
Boehringer Ingelheim and Gubra Join Forces to Identify and Validate Innovative Peptides for the Treatment of Obesity
Hørsholm, Denmark & Ingelheim, Germany: The research agreement builds upon the successful relationship between Boehringer Ingelheim and Gubra and expands…
Read More »